טוען...

A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia

Nintedanib (BIBF 1120), a potent multikinase inhibitor of VEGFR-1/-2/-3, FGFR-1/-2/-3 and PDGFR-α/-β, exerts growth inhibitory and pro-apoptotic effects in myeloid leukemic cells, especially when used in combination with cytarabine. This phase I study evaluated nintedanib in combination with low-dos...

תיאור מלא

שמור ב:

מידע ביבליוגרפי
הוצא לאור ב:	PLoS One
Main Authors:	Schliemann, Christoph, Gerss, Joachim, Wiebe, Stefanie, Mikesch, Jan-Henrik, Knoblauch, Nicola, Sauer, Tim, Angenendt, Linus, Kewitz, Tobias, Urban, Marc, Butterfass-Bahloul, Trude, Edemir, Sabine, Vehring, Kerstin, Müller-Tidow, Carsten, Berdel, Wolfgang E., Krug, Utz
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Public Library of Science 2016
נושאים:	Research Article
גישה מקוונת:	https://ncbi.nlm.nih.gov/pmc/articles/PMC5055288/ https://ncbi.nlm.nih.gov/pubmed/27716819 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0164499
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia

פריטים דומים